Brief: DBP International AB And Vivo Biopharma LLC Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
19/09/2023 21:29
Sept 19 (Reuters) - Double Bond Pharmaceutical
International Ab (Publ) DBPHAb.TE :
* SUPPLEMENT TO PRESS RELEASE: DBP INTERNATIONAL AB AND VIVO
BIOPHARMA LLC ENTER INTO ASSET PURCHASE AND COLLABORATION
AGREEMENTS TO DEVELOP AND COMMERCIALIZE A NOVEL GLIOBLASTOMA
TREATMENT
* DBP IS ENTITLED TO RECEIVE MORE THAN $150 MILLION OF
MILESTONE
AND ROYALTY PAYMENTS FROM VIVO
* BOTH PARTIES ANTICIPATE CLOSING TRANSACTION BY Q1, 2024.
Source text for Eikon: ID:nWkr5LP9y1
Further company coverage: DBPHAb.TE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Double Bond Pharmaceutical International AB (publ)
See all newsBrief: DBP International AB And Vivo Biopharma LLC Revised Asset Purchase And Collaboration Agreements
Brief: DBP International AB And Vivo Biopharma LLC Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: DBP And Vivo Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: Double Bond Pharmaceutical Says Positive Response For SI-053 From Ethical Committee In Netherlands Has Been Received
Brief: Double Bond To Cooperate With Belarus State Medical University